Natural killer cell-based immunotherapy for cancer

被引：2

作者：

Ma, Shoubao ^{[1
,2
,3
]}

Yu, Jianhua ^{[4
,5
,6
]}

Caligiuri, Michael A. ^{[1
,2
,3
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500E Duarte Rad, Los Angeles, CA 91010 USA

[2] City Hope Natl Med Ctr, Hematol Malignancies Res Inst, Los Angeles, CA USA

[3] City Hope Comprehens Canc Ctr, Los Angeles, CA USA

[4] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol & Oncol, 1001 Hlth Sci Rd, Irvine, CA 92697 USA

[5] Univ Calif Irvine, Inst Precis Canc Therapeut & Immuno Oncol, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[6] Univ Calif Irvine, Clemons Family Ctr Transformat Canc Res, Irvine, CA USA

来源：

JOURNAL OF IMMUNOLOGY | 2025年 / 214卷 / 07期

基金：

美国国家卫生研究院;

关键词：

cancer immunotherapy; CAR NK cells; natural killer cells; NK cell engagers; MOLONEY LEUKEMIA-CELLS; ACUTE MYELOID-LEUKEMIA; MOUSE LYMPHOID-CELLS; TGF-BETA RECEPTOR; BLOOD NK CELLS; PHASE-I TRIAL; T-CELLS; ADOPTIVE TRANSFER; CYTOMEGALOVIRUS-INFECTION; RECOMBINANT INTERLEUKIN-2;

D O I：

10.1093/jimmun/vkaf036

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Natural killer (NK) cells are emerging as a promising tool for cancer immunotherapy due to their innate ability to selectively recognize and eliminate cancer cells. Over the past 3 decades, strategies to harness NK cells have included cytokines, small molecules, antibodies, and the adoptive transfer of autologous or allogeneic NK cells, both unmodified and genetically engineered. Despite favorable safety profiles in clinical trials, challenges such as limited in vivo persistence, exhaustion, and the suppressive tumor microenvironment continue to hinder their efficacy and durability. This review categorizes NK cell-based therapies into 3 major approaches: (i) cellular therapies, including unmodified and chimeric antigen receptor-engineered NK cells; (ii) cytokine-based strategies such as interleukin-2 and interleukin-15 derivatives; and (iii) antibody-based therapies, including immune checkpoint inhibitors and NK cell engagers. We highlight these advancements, discuss current limitations, and propose strategies to optimize NK cell-based therapies for improved cancer treatment outcomes.

引用

页码：1444 / 1456

页数：13

共 192 条

[1] Targeted In Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform [J].

Andorko, James I. ;

Russell, Ronnie M. ;

Schnepp, Bruce C. ;

Singh, Ramesh ;

Boral, Debasish ;

O'Malley, Thomas ;

Kuri-Cervantes, Leticia ;

Medi, Muneeswara B. ;

Culp, Timothy D. ;

Johnson, Philip R. .

BLOOD, 2023, 142

[2] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[3] Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].

Arai, S. ;

Meagher, R. ;

Swearingen, M. ;

Myint, H. ;

Rich, E. ;

Martinson, J. ;

Klingemann, H. .

CYTOTHERAPY, 2008, 10 (06) :625-632

[4] Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy [J].

Arellano-Ballestero, Helena ;

Zubiak, Agnieszka ;

Dally, Chris ;

Orchard, Kim ;

Alrubayyi, Aljawharah ;

Charalambous, Xenia ;

Michael, Melina ;

Torrance, Robert ;

Eales, Trinity ;

Das, Kushal ;

Tran, Maxine G. B. ;

Sabry, May ;

Peppa, Dimitra ;

Lowdell, Mark W. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07)

[5] Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein [J].

Bachanova, Veronika ;

Cooley, Sarah ;

Defor, Todd E. ;

Verneris, Michael R. ;

Zhang, Bin ;

McKenna, David H. ;

Curtsinger, Julie ;

Panoskaltsis-Mortari, Angela ;

Lewis, Dixie ;

Hippen, Keli ;

McGlave, Philip ;

Weisdorf, Daniel J. ;

Blazar, Bruce R. ;

Miller, Jeffrey S. .

BLOOD, 2014, 123 (25) :3855-3863

[6] Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant [J].

Bednarski, Jeffrey J. ;

Zimmerman, Clare ;

Berrien-Elliott, Melissa M. ;

Foltz, Jennifer A. ;

Becker-Hapak, Michelle ;

Neal, Carly C. ;

Foster, Mark ;

Schappe, Timothy ;

McClain, Ethan ;

Pence, Patrick P. ;

Desai, Sweta ;

Kersting-Schadek, Samantha ;

Wong, Pamela ;

Russler-Germain, David A. ;

Fisk, Bryan ;

Lie, Wen-Rong ;

Eisele, Jeremy ;

Hyde, Stephanie ;

Bhatt, Sima T. ;

Griffith, Obi L. ;

Griffith, Malachi ;

Petti, Allegra A. ;

Cashen, Amanda F. ;

Fehniger, Todd A. .

BLOOD, 2022, 139 (11) :1670-1683

[7] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Mishra, Anjali ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Becknell, Brian ;

Baiocchi, Robert A. ;

Zhang, Jianying ;

Yu, Jianhua ;

Smith, Megan K. ;

Greenfield, Carli N. ;

Porcu, Pierluigi ;

Devine, Steven M. ;

Rotem-Yehudar, Rinat ;

Lozanski, Gerard ;

Byrd, John C. ;

Caligiuri, Michael A. .

BLOOD, 2010, 116 (13) :2286-2294

[8] Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation [J].

Berjis, Abdulla ;

Muthumani, Deeksha ;

Aguilar, Oscar A. ;

Pomp, Oz ;

Johnson, Omar ;

Finck, Amanda V. ;

Engel, Nils W. ;

Chen, Linhui ;

Plachta, Nicolas ;

Scholler, John ;

Lanier, Lewis L. ;

June, Carl H. ;

Sheppard, Neil C. .

NATURE COMMUNICATIONS, 2024, 15 (01)

[9] Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia [J].

Berrien-Elliott, Melissa M. ;

Foltz, Jennifer A. ;

Russler-Germain, David A. ;

Neal, Carly C. ;

Tran, Jennifer ;

Gang, Margery ;

Wong, Pamela ;

Fisk, Bryan ;

Cubitt, Celia C. ;

Marin, Nancy D. ;

Zhou, Alice Y. ;

Jacobs, Miriam T. ;

Foster, Mark ;

Schappe, Timothy ;

McClain, Ethan ;

Kersting-Schadek, Samantha ;

Desai, Sweta ;

Pence, Patrick ;

Becker-Hapak, Michelle ;

Eisele, Jeremy ;

Mosior, Matthew ;

Marsala, Lynne ;

Griffith, Obi L. ;

Griffith, Malachi ;

Khan, Saad M. ;

Spencer, David H. ;

DiPersio, John F. ;

Romee, Rizwan ;

Uy, Geoffrey L. ;

Abboud, Camille N. ;

Ghobadi, Armin ;

Westervelt, Peter ;

Stockerl-Goldstein, Keith ;

Schroeder, Mark A. ;

Wan, Fei ;

Lie, Wen-Rong ;

Soon-Shiong, Patrick ;

Petti, Allegra A. ;

Cashen, Amanda F. ;

Fehniger, Todd A. .

SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (633)

[10] Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia [J].

Berrien-Elliott, Melissa M. ;

Cashen, Amanda F. ;

Cubitt, Celia C. ;

Neal, Carly C. ;

Wong, Pamela ;

Wagner, Julia A. ;

Foster, Mark ;

Schappe, Timothy ;

Desai, Sweta ;

McClain, Ethan ;

Becker-Hapak, Michelle ;

Foltz, Jennifer A. ;

Cooper, Matthew L. ;

Jaeger, Natalia ;

Srivatsan, Sridhar Nonavinkere ;

Gao, Feng ;

Romee, Rizwan ;

Abboud, Camille N. ;

Uy, Geoffrey L. ;

Westervelt, Peter ;

Jacoby, Meagan A. ;

Pusic, Iskra ;

Stockerl-Goldstein, Keith E. ;

Schroeder, Mark A. ;

DiPersio, John ;

Fehniger, Todd A. .

CANCER DISCOVERY, 2020, 10 (12) :1854-1871

← 1 2 3 4 5 6 7 8 9 10 →